

Hai-Bo Wang,* Yue-Qing Pu,
Jia-Hui Chen and Jin-Tang WangDepartment of Applied Chemistry, College of
Science, Nanjing University of Technology,
Xinmofan Road No.5 Nanjing, Nanjing 210009,
People's Republic of ChinaCorrespondence e-mail:
wanghaibo@njut.edu.cn

Key indicators

Single-crystal X-ray study
 $T = 293\text{ K}$
Mean $\sigma(\text{C}-\text{C}) = 0.004\text{ \AA}$
 R factor = 0.055
 wR factor = 0.168
Data-to-parameter ratio = 14.8For details of how these key indicators were
automatically derived from the article, see
<http://journals.iucr.org/e>.Methyl 2-[[3-(2-methyl)phenyl-1,2,4-
oxadiazol-5-yl]methoxy]phenylacetateThe title compound, $\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_4$, was synthesized by the
reaction of methyl (2-hydroxyphenyl)acetate and 3-(2-methyl-
phenyl)-5-chloromethyl-1,2,4-oxadiazole. $\text{C}-\text{H}\cdots\text{N}$ -type
hydrogen bonds are observed in the molecular structure. In
the crystal structure, there are weak intermolecular $\text{C}-\text{H}\cdots\text{O}$
hydrogen bonds and $\text{C}-\text{H}\cdots\pi$ interactions.Received 1 April 2005
Accepted 13 April 2005
Online 23 April 2005

Comment



1,2,4-Oxadiazole derivatives are of great interest because of
their biological properties. Some derivatives of 1,2,4-
oxadiazoles have intrinsic analgesic (Terashita *et al.*, 2002),
anti-inflammatory (Nicolaidis *et al.*, 1998) and anti-
picornaviral (Romero, 2001) properties, and show high effi-
cacy as agonists [*e.g.* for muscarinic (Macor *et al.*, 1996),
adrenergic (Quagliato & Andrae, 2002) and 5-hydroxy-trypt-
tamine (Gur *et al.*, 2001)] and antagonists [*e.g.* for angiotensin
(Naka & Kubo, 1999) and adhesion agents (Juraszyk *et al.*,
1997)] for different receptors. We report here the crystal
structure of the title compound, (I).The molecular structure of (I) is shown in Fig. 1, and
selected bond lengths and bond angles are given in Table 1.
The C4–C9 and C13–C18 benzene rings form dihedral angles

Figure 1

A view of the molecular structure of (I), showing the atom-numbering
scheme. Displacement ellipsoids are drawn at the 30% probability level
and H atoms are shown as small spheres of arbitrary radii. Hydrogen
bonds are shown as dashed lines.




Figure 2
The short C—H...O and C—H... π interactions (dashed lines) in the crystal structure of (I).

of 11.3 (2) and 13.7 (1)°, respectively, with the oxadiazole ring.

In the molecular structure, C—H...N type hydrogen bonds are observed. In the crystal structure, the molecules are linked by C—H...O hydrogen bonds and C—H... π interactions (Table 2 and Fig. 2), leading to the formation of a three-dimensional network.

Experimental

Methyl (2-hydroxyphenyl)acetate (20 mmol) was dissolved in acetone (20 ml) and potassium carbonate (30 mmol) was added in one portion. 3-(2-Methylphenyl)-5-chloromethyl-1,2,4-oxadiazole (20 mmol) in acetone (20 ml) was added to this mixture. The resulting mixture was refluxed for 6 h and then concentrated under reduced pressure to afford crude compound (I). Pure compound (I) was obtained by recrystallization from ethyl acetate (m.p. 339–341 K). Crystals of (I) suitable for X-ray diffraction were obtained by slow evaporation of an ethanol solution. Spectroscopic analysis: ^1H NMR (CDCl_3 , δ , p.p.m.): 7.99–8.00 (*m*, 1H), 7.37–7.39 (*m*, 1H), 7.31–7.32 (*m*, 2H), 7.23–7.29 (*m*, 2H), 6.99–7.03 (*m*, 2H), 5.37 (*s*, 2H), 3.74 (*s*, 2H), 3.69 (*s*, 3H), 2.62 (*s*, 3H).

Crystal data

$\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_4$	$D_x = 1.308 \text{ Mg m}^{-3}$
$M_r = 338.35$	Mo $K\alpha$ radiation
Monoclinic, $P2_1/c$	Cell parameters from 25 reflections
$a = 11.444$ (2) Å	$\theta = 9\text{--}12^\circ$
$b = 7.9540$ (16) Å	$\mu = 0.09 \text{ mm}^{-1}$
$c = 19.356$ (4) Å	$T = 293$ (2) K
$\beta = 102.83$ (3)°	Rod, colourless
$V = 1717.9$ (6) Å ³	$0.40 \times 0.20 \times 0.20 \text{ mm}$
$Z = 4$	

Data collection

Enraf-Nonius CAD-4 diffractometer	$\theta_{\text{max}} = 26.0^\circ$
$\omega/2\theta$ scans	$h = 0 \rightarrow 14$
3535 measured reflections	$k = 0 \rightarrow 9$
3361 independent reflections	$l = -23 \rightarrow 23$
1923 reflections with $I > 2\sigma(I)$	3 standard reflections
$R_{\text{int}} = 0.033$	every 200 reflections
	intensity decay: none

Refinement

Refinement on F^2	$w = 1/[\sigma^2(F_o^2) + (0.08P)^2]$
$R[F^2 > 2\sigma(F^2)] = 0.055$	where $P = (F_o^2 + 2F_c^2)/3$
$wR(F^2) = 0.168$	$(\Delta/\sigma)_{\text{max}} = 0.001$
$S = 1.03$	$\Delta\rho_{\text{max}} = 0.20 \text{ e \AA}^{-3}$
3361 reflections	$\Delta\rho_{\text{min}} = -0.20 \text{ e \AA}^{-3}$
227 parameters	Extinction correction: <i>SHELXL97</i>
H-atom parameters constrained	(Sheldrick, 1997)
	Extinction coefficient: 0.014 (2)

Table 1
Selected geometric parameters (Å, °).

O1—C2	1.324 (3)	N2—C11	1.282 (3)
O1—C1	1.437 (4)	N2—C12	1.386 (3)
O2—C2	1.210 (3)	C2—C3	1.498 (4)
O3—C9	1.381 (3)	C3—C4	1.502 (4)
O3—C10	1.405 (3)	C10—C11	1.483 (3)
O4—C11	1.329 (3)	C12—C13	1.470 (3)
O4—N1	1.418 (3)	C18—C19	1.497 (4)
N1—C12	1.297 (3)		
C2—O1—C1	116.9 (3)	O3—C9—C4	114.2 (2)
C9—O3—C10	119.53 (19)	O3—C10—C11	107.0 (2)
C11—O4—N1	105.99 (18)	N2—C11—O4	114.0 (2)
C12—N1—O4	103.4 (2)	N2—C11—C10	127.8 (2)
C11—N2—C12	102.8 (2)	O4—C11—C10	118.2 (2)
O2—C2—O1	123.0 (3)	N1—C12—N2	113.8 (2)
O2—C2—C3	124.1 (3)	N1—C12—C13	124.4 (2)
O1—C2—C3	112.9 (3)	N2—C12—C13	121.8 (2)
C2—C3—C4	113.0 (2)	C14—C13—C12	116.8 (2)
C9—C4—C3	119.5 (2)	C18—C13—C12	123.8 (2)
C5—C4—C3	123.3 (3)	C17—C18—C19	118.7 (3)
C8—C9—O3	124.1 (2)	C13—C18—C19	124.2 (2)

Table 2
Hydrogen-bond geometry (Å, °).

Cg1 is the centroid of the C4–C9 ring.

$D\text{—}H\cdots A$	$D\text{—}H$	$H\cdots A$	$D\cdots A$	$D\text{—}H\cdots A$
C1—H1B...O2 ⁱ	0.96	2.53	3.480 (4)	169
C8—H8A...O2 ⁱⁱ	0.93	2.54	3.365 (3)	149
C14—H14A...N2	0.93	2.47	2.839 (3)	104
C19—H19C...N1	0.96	2.54	2.880 (4)	101
C10—H10A...Cg1 ⁱⁱⁱ	0.97	2.82	3.592 (3)	138

Symmetry codes: (i) $-x + 1, y - \frac{1}{2}, -z + \frac{1}{2}$; (ii) $-x + 1, -y + 1, -z$.

All H atoms were placed in calculated positions, with C—H distances in the range 0.93–0.97 Å. They were included in the riding-model approximation, with $U_{\text{iso}}(\text{H}) = 1.2$ or 1.5 (methyl) times $U_{\text{eq}}(\text{C})$.

Data collection: *CAD-4 Software* (Enraf-Nonius, 1989); cell refinement: *CAD-4 Software*; data reduction: *XCAD4* (Harms & Wocadlo, 1995); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *SHELXTL* (Siemens, 1996); software used to prepare material for publication: *SHELXL97*.

References

- Enraf-Nonius (1989). *CAD-4 Software*. Version 5.0. Enraf-Nonius, Delft, The Netherlands.
Gur, E., Dremencov, E., Lerer, B. & Newman, M. E. (2001). *Eur. J. Pharmacol.* **411**, 115–122.
Harms, K. & Wocadlo, S. (1995). *XCAD4*. University of Marburg, Germany.

- Juraszyk, H., Gante, J., Wurziger, H., Bernotat-Danielowski, S. & Melzer, G. (1997). PCT Int. Appl. No. 9744333.
- Macor, J. E., Ordway, T., Smith, R. L., Verhoest, P. R. & Mack, R. A. (1996). *J. Org. Chem.* **61**, 3228–3229.
- Naka, T. & Kubo, K. (1999). *Curr. Pharm. Des.* **5**, 453–472.
- Nicolaidis, D. N., Fylaktakidou, K. C., Litinas, K. E. & Hadjipavlou-Litina, D. (1998). *Eur. J. Med. Chem.* **33**, 715–724.
- Quagliato, D. A. & Andrae, P. M. (2002). PCT Int. Appl. WO, 0206250.
- Romero, J. R. (2001). *Expert Opin. Invest. Drugs*, **10**, 369–379.
- Sheldrick, G. M. (1997). *SHELXL97* and *SHELXS97*. University of Göttingen, Germany.
- Siemens (1996). *SHELXTL*. Version 5.06. Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.
- Terashita, Z., Naruo, K. & Morimoto, S. (2002). PCT Int. Appl. WO, 0260439.